The field of synthetic antibodies is an area that should be continually monitored. Pivotal clinical trials are underway with cancer vaccines, and synthetic HIV vaccines are moving into advanced preclinical studies. Cost issues are being addressed in an attempt to make the products affordable in poor countries where these vaccines are urgently needed.
|Number of pages||3|
|State||Published - 1 May 2005|